Search
Tedisamil
go.drugbank.com/drugs/DB06200ExperimentalIt is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration. … Tedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter.
Ibrexafungerp
go.drugbank.com/drugs/DB12471Approved[A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity. … [A235384,L34349] It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole antifungals.
Dithiazanine
go.drugbank.com/drugs/DB11516ApprovedVet approvedWithdrawnDithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032]
Felypressin
go.drugbank.com/drugs/DB00093InvestigationalIt is a non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth
Mixtures: PRESTIGE® NFFostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigational[L14867,L14917] Targeting gp120 subunits is a new and novel therapeutic approach to HIV-1 infection, and the addition of attachment inhibitors, like temsavir, to the armament of therapies targeted against
D-amino-acid oxidase
go.drugbank.com/bio_entities/BE0004141TargetEnzymeHumansEnzyme secreted into the lumen of the intestine may not be catalytically active and could instead be proteolytically cleaved into peptides with antimicrobial activity (By similarity).
Synonyms: DAONCX 701
go.drugbank.com/drugs/DB05409ExperimentalNitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.
Nirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigational[A262561] Nirogacestat was approved under the brand name OGSIVEO on November 27, 2023, by the FDA for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. … Desmoid tumors are typically characterized by aberrant activation in Notch signaling.
Emicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigational[A31279, L1016] It was created by Chugai Pharmaceuticals Co. Ltd. and co-developed with Roche and Genentech.[L1015] … The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.
Adrafinil
go.drugbank.com/drugs/DB08925ApprovedWithdrawnAdrafinil does not currently have FDA approval and is thus unregulated in the United States. … It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission.